References
1. Jiang Y, Zhang J, Guo D, et al. Entire ABL1 Gene Deletion Without
BCR/ABL1 Rearrangement in a Female Patient with B-Cell Precursor Acute
Lymphoblastic Leukemia. Onco Targets Ther 2020;13 :783-90 doi:
10.2147/ott.S238336[published Online First: Epub Date]|.
2. Rafei H, Kantarjian HM, Jabbour EJ. Recent advances in the treatment
of acute lymphoblastic leukemia. Leukemia & lymphoma
2019;60 (11):2606-21 doi:
10.1080/10428194.2019.1605071[published Online First: Epub
Date]|.
3. Bleyer A, Barr R, Hayes-Lattin B, Thomas D, Ellis C, Anderson B. The
distinctive biology of cancer in adolescents and young adults. Nature
reviews. Cancer 2008;8 (4):288-98 doi:
10.1038/nrc2349[published Online First: Epub Date]|.
4. Sender L, Zabokrtsky KB. Adolescent and young adult patients with
cancer: a milieu of unique features. Nature reviews. Clinical oncology
2015;12 (8):465-80 doi: 10.1038/nrclinonc.2015.92[published
Online First: Epub Date]|.
5. Miller KD, Fidler-Benaoudia M, Keegan TH, Hipp HS, Jemal A, Siegel
RL. Cancer statistics for adolescents and young adults, 2020. CA: a
cancer journal for clinicians 2020;70 (6):443-59 doi:
10.3322/caac.21637[published Online First: Epub Date]|.
6. Friend BD, Schiller GJ. Closing the gap: Novel therapies in treating
acute lymphoblastic leukemia in adolescents and young adults. Blood
reviews 2018;32 (2):122-29 doi:
10.1016/j.blre.2017.09.005[published Online First: Epub
Date]|.
7. Anderson C, Lund JL, Weaver MA, Wood WA, Olshan AF, Nichols HB.
Noncancer mortality among adolescents and young adults with cancer.
Cancer 2019;125 (12):2107-14 doi: 10.1002/cncr.32063[published
Online First: Epub Date]|.
8. Katsibardi K, Papadakis V, Charisiadou A, Pangalis A,
Polychronopoulou S. Blood stream infections throught the entire course
of acute lymphoblastic leukemia treatment. Neoplasma
2011;58 (4):326-30 doi: 10.4149/neo_2011_04_326[published
Online First: Epub Date]|.
9. Cui L, Li ZG, Chai YH, et al. Outcome of children with newly
diagnosed acute lymphoblastic leukemia treated with CCLG-ALL 2008: The
first nation-wide prospective multicenter study in China. American
journal of hematology 2018;93 (7):913-20 doi:
10.1002/ajh.25124[published Online First: Epub Date]|.
10. Trecarichi EM, Pagano L, Candoni A, et al. Current epidemiology and
antimicrobial resistance data for bacterial bloodstream infections in
patients with hematologic malignancies: an Italian multicentre
prospective survey. Clinical microbiology and infection : the official
publication of the European Society of Clinical Microbiology and
Infectious Diseases 2015;21 (4):337-43 doi:
10.1016/j.cmi.2014.11.022[published Online First: Epub
Date]|.
11. Mikulska M, Viscoli C, Orasch C, et al. Aetiology and resistance in
bacteraemias among adult and paediatric haematology and cancer patients.
The Journal of infection 2014;68 (4):321-31 doi:
10.1016/j.jinf.2013.12.006[published Online First: Epub
Date]|.
12. Inaba H, Pei D, Wolf J, et al. Infection-related complications
during treatment for childhood acute lymphoblastic leukemia. Annals of
oncology : official journal of the European Society for Medical Oncology
2017;28 (2):386-92 doi: 10.1093/annonc/mdw557[published Online
First: Epub Date]|.
13. Veal GJ, Hartford CM, Stewart CF. Clinical pharmacology in the
adolescent oncology patient. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology
2010;28 (32):4790-9 doi: 10.1200/jco.2010.28.3473[published
Online First: Epub Date]|.
14. Stock W, Douer D, DeAngelo DJ, et al. Prevention and management of
asparaginase/pegasparaginase-associated toxicities in adults and older
adolescents: recommendations of an expert panel. Leukemia & lymphoma
2011;52 (12):2237-53 doi:
10.3109/10428194.2011.596963[published Online First: Epub
Date]|.
15. Husson O, Huijgens PC, van der Graaf WTA. Psychosocial challenges
and health-related quality of life of adolescents and young adults with
hematologic malignancies. Blood 2018;132 (4):385-92 doi:
10.1182/blood-2017-11-778555[published Online First: Epub
Date]|.
16. Pritchard MT, Butow PN, Stevens MM, Duley JA. Understanding
medication adherence in pediatric acute lymphoblastic leukemia: a
review. Journal of pediatric hematology/oncology
2006;28 (12):816-23 doi:
10.1097/01.mph.0000243666.79303.45[published Online First: Epub
Date]|.
17. Tebbi CK, Cummings KM, Zevon MA, Smith L, Richards M, Mallon J.
Compliance of pediatric and adolescent cancer patients. Cancer
1986;58 (5):1179-84 doi:
10.1002/1097-0142(19860901)58:5<1179::aid-cncr2820580534>3.0.co;2-e[published
Online First: Epub Date]|.
18. Liang T, Xu C, Cheng Q, Tang Y, Zeng H, Li X. Epidemiology, Risk
Factors, and Clinical Outcomes of Bloodstream Infection due to
Extended-Spectrum Beta-Lactamase-Producing Escherichia coli and
Klebsiella pneumoniae in Hematologic Malignancy: A Retrospective Study
from Central South China. Microbial drug resistance (Larchmont, N.Y.)
2021;27 (6):800-08 doi: 10.1089/mdr.2020.0033[published Online
First: Epub Date]|.
19. Gudiol C, Calatayud L, Garcia-Vidal C, et al. Bacteraemia due to
extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in
cancer patients: clinical features, risk factors, molecular epidemiology
and outcome. The Journal of antimicrobial chemotherapy
2010;65 (2):333-41 doi: 10.1093/jac/dkp411[published Online
First: Epub Date]|.
20. Kim SH, Kwon JC, Choi SM, et al. Escherichia coli and Klebsiella
pneumoniae bacteremia in patients with neutropenic fever: factors
associated with extended-spectrum β-lactamase production and its impact
on outcome. Annals of hematology 2013;92 (4):533-41 doi:
10.1007/s00277-012-1631-y[published Online First: Epub
Date]|.
21. Trecarichi EM, Tumbarello M, Spanu T, et al. Incidence and clinical
impact of extended-spectrum-beta-lactamase (ESBL) production and
fluoroquinolone resistance in bloodstream infections caused by
Escherichia coli in patients with hematological malignancies. The
Journal of infection 2009;58 (4):299-307 doi:
10.1016/j.jinf.2009.02.002[published Online First: Epub
Date]|.
22. Cordery RJ, Roberts CH, Cooper SJ, Bellinghan G, Shetty N.
Evaluation of risk factors for the acquisition of bloodstream infections
with extended-spectrum beta-lactamase-producing Escherichia coli and
Klebsiella species in the intensive care unit; antibiotic management and
clinical outcome. The Journal of hospital infection
2008;68 (2):108-15 doi: 10.1016/j.jhin.2007.10.011[published
Online First: Epub Date]|.
23. Jarløv JO, Højbjerg T, Busch-Sørensen C, et al. Coagulase-negative
Staphylococci in Danish blood cultures: species distribution and
antibiotic susceptibility. The Journal of hospital infection
1996;32 (3):217-27 doi:
10.1016/s0195-6701(96)90148-6[published Online First: Epub
Date]|.
24. Zhu GQ, Xu CH, Lin QS, et al. [Analysis of pathogens and clinical
characteristics of bloodstream infection in neutropenic children with
hematological malignancies from 2014 to 2018]. Zhonghua xue ye xue za
zhi = Zhonghua xueyexue zazhi 2020;41 (8):655-60 doi:
10.3760/cma.j.issn.0253-2727.2020.08.007[published Online First: Epub
Date]|.
25. Basu SK, Fernandez ID, Fisher SG, Asselin BL, Lyman GH. Length of
stay and mortality associated with febrile neutropenia among children
with cancer. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2005;23 (31):7958-66 doi:
10.1200/jco.2005.01.6378[published Online First: Epub
Date]|.
26. Kameda K, Kimura SI, Akahoshi Y, et al. High Incidence of Afebrile
Bloodstream Infection Detected by Surveillance Blood Culture in Patients
on Corticosteroid Therapy after Allogeneic Hematopoietic Stem Cell
Transplantation. Biology of blood and marrow transplantation : journal
of the American Society for Blood and Marrow Transplantation
2016;22 (2):371-77 doi: 10.1016/j.bbmt.2015.09.019[published
Online First: Epub Date]|.
27. van Walraven C, Wong J. Independent influence of negative blood
cultures and bloodstream infections on in-hospital mortality. BMC
infectious diseases 2014;14 :36 doi:
10.1186/1471-2334-14-36[published Online First: Epub
Date]|.
28. Apostolopoulou E, Raftopoulos V, Terzis K, Elefsiniotis I. Infection
Probability Score, APACHE II and KARNOFSKY scoring systems as predictors
of bloodstream infection onset in hematology-oncology patients. BMC
infectious diseases 2010;10 :135 doi:
10.1186/1471-2334-10-135[published Online First: Epub
Date]|.
29. [Chinese guidelines for the clinical application of antibacterial
drugs for agranulocytosis with fever (2020)]. Zhonghua xue ye xue za
zhi = Zhonghua xueyexue zazhi 2020;41 (12):969-78 doi:
10.3760/cma.j.issn.0253-2727.2020.12.001[published Online First: Epub
Date]|.
30. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant,
extensively drug-resistant and pandrug-resistant bacteria: an
international expert proposal for interim standard definitions for
acquired resistance. Clinical microbiology and infection : the official
publication of the European Society of Clinical Microbiology and
Infectious Diseases 2012;18 (3):268-81 doi:
10.1111/j.1469-0691.2011.03570.x[published Online First: Epub
Date]|.
31. Tang Y, Wu X, Cheng Q, Li X. Inappropriate initial antimicrobial
therapy for hematological malignancies patients with Gram-negative
bloodstream infections. Infection 2020;48 (1):109-16 doi:
10.1007/s15010-019-01370-x[published Online First: Epub
Date]|.
32. Tang Y, Cheng Q, Yang Q, et al. Prognostic factors and scoring model
of hematological malignancies patients with bloodstream infections.
Infection 2018;46 (4):513-21 doi:
10.1007/s15010-018-1151-3[published Online First: Epub
Date]|.
33. Zilberberg MD, Shorr AF, Micek ST, Vazquez-Guillamet C, Kollef MH.
Multi-drug resistance, inappropriate initial antibiotic therapy and
mortality in Gram-negative severe sepsis and septic shock: a
retrospective cohort study. Critical care (London, England)
2014;18 (6):596 doi: 10.1186/s13054-014-0596-8[published
Online First: Epub Date]|.